Table 1 Demographics and baseline characteristics
Baseline characteristics (at the time of the switch) | |
|---|---|
No. of patients | 44 |
No. of eyes | 57 |
Male, n (%) | 30 (68.2) |
Age (years), mean (range) | 64.4 (41–79) |
Type 2 diabetes, n (%) | 39 (88.6) |
Right eyes, n (%) | 28 (49.1) |
Phakic, n (%) | 45 (78.9) |
Baseline BCVA (letters), median (IQR) | 69 (62–89) |
Baseline CMT (μm), median (IQR) | 400 (358–451) |
No. of ranibiumab injections, mean (range) | 12 (3- 21) |
Duration of ranibizumab treatment (months), mean (range) | 17.9 (2.7–42.3) |
Interval between last ranibizumab and first aflibercept (days), mean (range) | 62.9 (28–119) |
No. of eyes with other treatments before first ranibizumab, n (%) | |
Focal/grid laser | 28 (49.1) |
Panretinal photocoagulation | 17(29.8) |
Triamcinolone | 5(8.8) |
No. of eyes with other treatments during treatment with ranibizumab, n (%) | |
Focal/grid laser | 6(10.5) |
Panretinal photocoagulation | 9(15.8) |
Vitrectomy | 1(1.7) |